Selected research
Industry Research
Lyophilized IVIG Industry Research Report 2026
Market perspective
The global Lyophilized IVIG market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Lyophilized IVIG is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Lyophilized IVIG is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Lyophilized IVIG is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Lyophilized IVIG include Biotest, BPL, CBPO, CNBG, CSL, Grifols, Kedrion, LFB Group and Octapharma, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Lyophilized IVIG market in terms of revenue (US$ million) and, where applicable, sales volume (k units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/k units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Lyophilized IVIG Market by Company
Biotest
BPL
CBPO
CNBG
CSL
Grifols
Kedrion
LFB Group
Octapharma
Hualan Bio
Shanghai RAAS
Sichuan Yuanda Shuyang
Takeda
Lyophilized IVIG Segment by Type
2.5g
1.25g
Lyophilized IVIG Segment by Application
Autoimmune Disease
Immunodeficiency
Acute Infection
Lyophilized IVIG Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Colombia
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Lyophilized IVIG market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Lyophilized IVIG and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Lyophilized IVIG.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Lyophilized IVIG manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Lyophilized IVIG by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Lyophilized IVIG in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- 2.5g
- 1.25g
Applications
- Autoimmune Disease
- Immunodeficiency
- Acute Infection
Companies covered
- Biotest
- BPL
- CBPO
- CNBG
- CSL
- Grifols
- Kedrion
- LFB Group
- Octapharma
- Hualan Bio
- Shanghai RAAS
- Sichuan Yuanda Shuyang
- Takeda
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Lyophilized IVIG Market Size (2021-2032)
- 2.2.2 Global Lyophilized IVIG Sales (2021-2032)
- 2.2.3 Global Lyophilized IVIG Market Average Price (2021-2032)
- 2.3 Lyophilized IVIG by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 2.5g
- 2.3.3 1.25g
- 2.4 Lyophilized IVIG by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Autoimmune Disease
- 2.4.3 Immunodeficiency
- 2.4.4 Acute Infection
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Lyophilized IVIG Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Lyophilized IVIG Sales (k units) of Manufacturers (2021-2026)
- 3.3 Global Lyophilized IVIG Revenue of Manufacturers (2021-2026)
- 3.4 Global Lyophilized IVIG Average Price by Manufacturers (2021-2026)
- 3.5 Global Lyophilized IVIG Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Lyophilized IVIG, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Lyophilized IVIG, Product Type & Application
- 3.8 Global Manufacturers of Lyophilized IVIG, Established Date
- 3.9 Global Lyophilized IVIG Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Biotest
- 4.1.1 Biotest Company Information
- 4.1.2 Biotest Business Overview
- 4.1.3 Biotest Lyophilized IVIG Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Biotest Lyophilized IVIG Product Portfolio
- 4.1.5 Biotest Recent Developments
- 4.2 BPL
- 4.2.1 BPL Company Information
- 4.2.2 BPL Business Overview
- 4.2.3 BPL Lyophilized IVIG Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 BPL Lyophilized IVIG Product Portfolio
- 4.2.5 BPL Recent Developments
- 4.3 CBPO
- 4.3.1 CBPO Company Information
- 4.3.2 CBPO Business Overview
- 4.3.3 CBPO Lyophilized IVIG Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 CBPO Lyophilized IVIG Product Portfolio
- 4.3.5 CBPO Recent Developments
- 4.4 CNBG
- 4.4.1 CNBG Company Information
- 4.4.2 CNBG Business Overview
- 4.4.3 CNBG Lyophilized IVIG Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 CNBG Lyophilized IVIG Product Portfolio
- 4.4.5 CNBG Recent Developments
- 4.5 CSL
- 4.5.1 CSL Company Information
- 4.5.2 CSL Business Overview
- 4.5.3 CSL Lyophilized IVIG Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 CSL Lyophilized IVIG Product Portfolio
- 4.5.5 CSL Recent Developments
- 4.6 Grifols
- 4.6.1 Grifols Company Information
- 4.6.2 Grifols Business Overview
- 4.6.3 Grifols Lyophilized IVIG Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Grifols Lyophilized IVIG Product Portfolio
- 4.6.5 Grifols Recent Developments
- 4.7 Kedrion
- 4.7.1 Kedrion Company Information
- 4.7.2 Kedrion Business Overview
- 4.7.3 Kedrion Lyophilized IVIG Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 Kedrion Lyophilized IVIG Product Portfolio
- 4.7.5 Kedrion Recent Developments
- 4.8 LFB Group
- 4.8.1 LFB Group Company Information
- 4.8.2 LFB Group Business Overview
- 4.8.3 LFB Group Lyophilized IVIG Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 LFB Group Lyophilized IVIG Product Portfolio
- 4.8.5 LFB Group Recent Developments
- 4.9 Octapharma
- 4.9.1 Octapharma Company Information
- 4.9.2 Octapharma Business Overview
- 4.9.3 Octapharma Lyophilized IVIG Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 Octapharma Lyophilized IVIG Product Portfolio
- 4.9.5 Octapharma Recent Developments
- 4.10 Hualan Bio
- 4.10.1 Hualan Bio Company Information
- 4.10.2 Hualan Bio Business Overview
- 4.10.3 Hualan Bio Lyophilized IVIG Sales, Revenue and Gross Margin (2021-2026)
- 4.10.4 Hualan Bio Lyophilized IVIG Product Portfolio
- 4.10.5 Hualan Bio Recent Developments
- 4.11 Shanghai RAAS
- 4.11.1 Shanghai RAAS Company Information
- 4.11.2 Shanghai RAAS Business Overview
- 4.11.3 Shanghai RAAS Lyophilized IVIG Sales, Revenue and Gross Margin (2021-2026)
- 4.11.4 Shanghai RAAS Lyophilized IVIG Product Portfolio
- 4.11.5 Shanghai RAAS Recent Developments
- 4.12 Sichuan Yuanda Shuyang
- 4.12.1 Sichuan Yuanda Shuyang Company Information
- 4.12.2 Sichuan Yuanda Shuyang Business Overview
- 4.12.3 Sichuan Yuanda Shuyang Lyophilized IVIG Sales, Revenue and Gross Margin (2021-2026)
- 4.12.4 Sichuan Yuanda Shuyang Lyophilized IVIG Product Portfolio
- 4.12.5 Sichuan Yuanda Shuyang Recent Developments
- 4.13 Takeda
- 4.13.1 Takeda Company Information
- 4.13.2 Takeda Business Overview
- 4.13.3 Takeda Lyophilized IVIG Sales, Revenue and Gross Margin (2021-2026)
- 4.13.4 Takeda Lyophilized IVIG Product Portfolio
- 4.13.5 Takeda Recent Developments
5 Global Lyophilized IVIG Market Scenario by Region
- 5.1 Global Lyophilized IVIG Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Lyophilized IVIG Sales by Region: 2021-2032
- 5.2.1 Global Lyophilized IVIG Sales by Region: 2021-2026
- 5.2.2 Global Lyophilized IVIG Sales by Region: 2027-2032
- 5.3 Global Lyophilized IVIG Revenue by Region: 2021-2032
- 5.3.1 Global Lyophilized IVIG Revenue by Region: 2021-2026
- 5.3.2 Global Lyophilized IVIG Revenue by Region: 2027-2032
- 5.4 North America Lyophilized IVIG Market Facts & Figures by Country
- 5.4.1 North America Lyophilized IVIG Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Lyophilized IVIG Sales by Country (2021-2032)
- 5.4.3 North America Lyophilized IVIG Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.4.6 Mexico
- 5.5 Europe Lyophilized IVIG Market Facts & Figures by Country
- 5.5.1 Europe Lyophilized IVIG Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Lyophilized IVIG Sales by Country (2021-2032)
- 5.5.3 Europe Lyophilized IVIG Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Russia
- 5.5.9 Spain
- 5.5.10 Netherlands
- 5.5.11 Switzerland
- 5.5.12 Sweden
- 5.5.13 Poland
- 5.6 Asia Pacific Lyophilized IVIG Market Facts & Figures by Country
- 5.6.1 Asia Pacific Lyophilized IVIG Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Lyophilized IVIG Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Lyophilized IVIG Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Lyophilized IVIG Market Facts & Figures by Country
- 5.7.1 South America Lyophilized IVIG Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Lyophilized IVIG Sales by Country (2021-2032)
- 5.7.3 South America Lyophilized IVIG Revenue by Country (2021-2032)
- 5.7.4 Brazil
- 5.7.5 Argentina
- 5.7.6 Chile
- 5.7.7 Colombia
- 5.8 Middle East and Africa Lyophilized IVIG Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Lyophilized IVIG Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Lyophilized IVIG Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Lyophilized IVIG Revenue by Country (2021-2032)
- 5.8.4 Egypt
- 5.8.5 South Africa
- 5.8.6 Israel
- 5.8.7 Türkiye
- 5.8.8 GCC Countries
6 Segment by Type
- 6.1 Global Lyophilized IVIG Sales by Type (2021-2032)
- 6.1.1 Global Lyophilized IVIG Sales by Type (2021-2032) & (k units)
- 6.1.2 Global Lyophilized IVIG Sales Market Share by Type (2021-2032)
- 6.2 Global Lyophilized IVIG Revenue by Type (2021-2032)
- 6.2.1 Global Lyophilized IVIG Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Lyophilized IVIG Revenue Market Share by Type (2021-2032)
- 6.3 Global Lyophilized IVIG Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Lyophilized IVIG Sales by Application (2021-2032)
- 7.1.1 Global Lyophilized IVIG Sales by Application (2021-2032) & (k units)
- 7.1.2 Global Lyophilized IVIG Sales Market Share by Application (2021-2032)
- 7.2 Global Lyophilized IVIG Revenue by Application (2021-2032)
- 7.2.1 Global Lyophilized IVIG Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Lyophilized IVIG Revenue Market Share by Application (2021-2032)
- 7.3 Global Lyophilized IVIG Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Lyophilized IVIG Value Chain Analysis
- 8.1.1 Lyophilized IVIG Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Lyophilized IVIG Production Mode & Process
- 8.2 Lyophilized IVIG Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Lyophilized IVIG Distributors
- 8.2.3 Lyophilized IVIG Customers
9 Global Lyophilized IVIG Analyzing Market Dynamics
- 9.1 Lyophilized IVIG Industry Trends
- 9.2 Lyophilized IVIG Industry Drivers
- 9.3 Lyophilized IVIG Industry Opportunities and Challenges
- 9.4 Lyophilized IVIG Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst